目的　报告 67例卵巢纯型未成熟畸胎瘤的治疗结果 ,并探讨影响患者生存的预后因素。方法　回顾性分析 :1 985-1 998年我院收治的 67例卵巢纯型未畸胎瘤的治疗情况。其中包括Ⅰ期 3 1例 ,Ⅱ期 4例 ,Ⅲ期 2例 ,Ⅳ期 1例 ,复发 2 7例 ,转移 2例。Ⅰ期患者首次手术均采用单侧附件切除 ,80年代后采用 4程联合化疗 (VAC ,PVB或 3程BEP)作为术后辅助化疗。对晚期复发肿瘤则采用化疗和反复手术相结合治疗。结果　全组 67例 ,生存 50例 ,总生存率 75%。但不同年代治疗结果差异很大。由 58-83年的 40 % ( 6/ 1 5) ,83-94年 79% ( 2 6/ 3 3 ) ,上升到 94-98年的 95% ( 1 8/ 1 9)。影响未成熟畸胎瘤预后的因素是临床分期和病理分级 ,以及正确的治疗方法。结论　卵巢未成熟畸瘤在目前已成为一个可治愈的肿瘤 ,早期患者 5年以上生存率已达 95% -1 0 0 % ,由于复发肿瘤可随化疗和时间推移恶性程度逆转 ,这一肿瘤特性为挽救复发病人提供了更多机会。因此未成熟畸胎瘤目前已成为卵巢恶性生殖细胞肿瘤中疗效最好的肿瘤 ,术前或化疗前肿瘤标记物检测 (包括AFP、CA1 99、CA1 2 5)有利于预后的判断 ,也有利于患者的随诊 Objective To report the results of 67 cases of pure ovarian immature teratoma and to explore the prognostic factors that affect the survival of patients. Methods Retrospective analysis: 1 985-1998 admitted to our hospital 67 cases of pure ovarian teratoma treatment. Including stage Ⅰ 31 cases, 4 cases of stage Ⅱ, Ⅲ in 2 cases, 1 case of stage Ⅳ, recurrence in 27 cases, 2 cases of transfer. The patients in stage Ⅰ were treated with unilateral accessory resection for the first time. Four courses of combined chemotherapy (VAC, PVB or 3-stage BEP) were used as postoperative adjuvant chemotherapy after 80 years. The late recurrent tumors were treated with chemotherapy combined with repeated surgery. Results The whole group of 67 cases, 50 cases of survival, the overall survival rate of 75%. However, different age treatment results vary widely. Rose from 40% (6/1 5) in 58-83 years to 79% (26/3 3) in 83-94 to 95% (18/1 9) in 1994-98. Factors affecting the prognosis of immature teratoma are clinical staging and pathological grade, as well as the correct treatment. Conclusions The immature ovarian tumor has become a curable tumor at present, and the survival rate of patients in early stage has reached 95% -100% after more than 5 years. Because the recurrence of tumor can be reversed with the degree of malignancy over time and chemotherapy, this tumor characteristic To save the recurrence of patients provides more opportunities. Therefore, immature teratoma has become the most effective tumor in ovarian malignant germ cell tumors, preoperative or preoperative detection of tumor markers (including AFP, CA1 99, CA1 2 5) is conducive to the prognosis of judgments, but also conducive to Follow-up of patients